Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05515627 · ClinicalTrials.gov registry record · Phase 1
Atezolizumab for Idiopathic Pulmonary Fibrosis
A Phase 1 study of Idiopathic Pulmonary Fibrosis, sponsored by Cedars-Sinai Medical Center.
- Active
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
- 1
- Study location
NCT05515627 is a Phase 1 study of Idiopathic Pulmonary Fibrosis that is active but no longer recruiting, run by Cedars-Sinai Medical Center. The registered enrollment target is 24 participants, below the 751-participant average among 51 other Idiopathic Pulmonary Fibrosis trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05515627, a Phase 1 study of Idiopathic Pulmonary Fibrosis, is active but no longer recruiting, sponsored by Cedars-Sinai Medical Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine the safety and preliminary efficacy of atezolizumab, an immune checkpoint inhibitor approved for the treatment of various cancers, in patients with idiopathic pulmonary fibrosis (IPF).
Conditions Studied
Interventions
- DRUG Atezolizumab
Study Locations (1)
California
- Cedars-Sinai Medical Center - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2023-02-15 |
| Est. Completion | 2027-04-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05515627
The ClinicalTrials.gov registry entry for NCT05515627 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 751-participant average among 51 other Idiopathic Pulmonary Fibrosis trials with a reported enrollment target (97% lower). The listed sponsor is Cedars-Sinai Medical Center, which has 339 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Idiopathic Pulmonary Fibrosis appearing as the primary indexed condition, and to 1 intervention - of which Atezolizumab is the first listed.
NCT05515627 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT05515627 about?
NCT05515627 is a clinical study titled "Atezolizumab for Idiopathic Pulmonary Fibrosis". The purpose of this study is to determine the safety and preliminary efficacy of atezolizumab, an immune checkpoint inhibitor approved for the treatment of various cancers, in patients with idiopathic pulmonary fibrosis (IPF).
What is the current status of trial NCT05515627?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2023-02-15. Estimated completion is 2027-04-30.
What conditions does trial NCT05515627 study?
This clinical trial studies the following conditions: Idiopathic Pulmonary Fibrosis.
What interventions are being tested in trial NCT05515627?
The interventions under investigation include: Atezolizumab (DRUG).
Who is sponsoring clinical trial NCT05515627?
This trial is sponsored by Cedars-Sinai Medical Center, which has 339 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05515627 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Idiopathic Pulmonary Fibrosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Dose-Escalation Study of Artesunate Patients With IPF
RECRUITING · Phase 1
-
Lung and Bone Marrow Transplantation for Lung and Bone Marrow Failure
RECRUITING · Phase 1
-
A Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GNS-3545 in Healthy Participants
RECRUITING · Phase 1
-
NAL ER IPF Respiratory Function and Safety Study
RECRUITING · Phase 1
-
Molecular Imaging Probes to Inform Heterogeneity in Idiopathic Pulmonary Fibrosis
RECRUITING · Phase 1
-
Study of Oral Epigallocatechin-3-gallate (EGCG) in IPF Patients
ACTIVE NOT RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.